Lead sponsor
Gan & Lee Pharmaceuticals.
14 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
14
Trials led
13
Active
3,584
Total enrollment
5
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
6
Phase 2
1
Phase 3
7
Trials by status
Not yet recruiting
3
Recruiting
6
Active, not recruiting
4
Completed
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsBMI ≥28Ph 3Active, not recruiting630
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsBMI ≥28Ph 3Recruiting420
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyBMI ≥28Ph 3Not yet recruiting140
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyBMI ≥28Ph 3Not yet recruiting140
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus—Ph 2Active, not recruiting90
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionBMI 26-35Ph 1Recruiting60
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionBMI ≤40Ph 1Recruiting32
A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight SubjectsBMI 24-28Ph 1Not yet recruiting30